Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hamps BioBOM:544312 -2.17%12 Return-on-Tangible-Equity is -14.04% as of Mar. 2026. GuruFocus rates BOM:544312 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 577 Healthcare Providers & Services companies, Hamps Bio ranks worse than 81.98% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Hamps Bio's annualized net income for the quarter that ended in Mar. 2026 was ₹-10.86 Mil. Hamps Bio's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹77.35 Mil. Therefore, Hamps Bio's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -14.04%.
The historical rank and industry rank for Hamps Bio's Return-on-Tangible-Equity or its related term are showing as below:
BOM:544312'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -9.44 Med: 12.08 Max: 30.31
Current: -9.17
During the past 5 years, Hamps Bio's highest Return-on-Tangible-Equity was 30.31%. The lowest was -9.44%. And the median was 12.08%.
BOM:544312's Return-on-Tangible-Equity is ranked worse than 81.98% of 577
companies
in the Healthcare Providers & Services industry
Industry Median: 10.86
vs BOM:544312: -9.17
Hamps Bio (BOM:544312) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Hamps Bio Return-on-Tangible-Equity Related Terms
Hamps Bio Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Hamps Bio's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hamps Bio Return-on-Tangible-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, Hamps Bio's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hamps Bio Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Hamps Bio's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Hamps Bio's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -14.04% mean?
Hamps Bio (BOM:544312) has a Return-on-Tangible-Equity of -14.04% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hamps Bio and its competitors. According to the industry distribution chart, Hamps Bio ranks #473 out of 577 companies in the Healthcare Providers & Services industry, placing it in the top 82%.
Is Hamps Bio's Return-on-Tangible-Equity too high?
Hamps Bio's current Return-on-Tangible-Equity is -14.04%. Based on the distribution chart, Hamps Bio ranks #473 out of 577 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Hamps Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Hamps Bio's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Hamps Bio ranks #473 out of 577 companies for Return-on-Tangible-Equity. This places Hamps Bio in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.86, based on 577 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hamps Bio and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hamps Bio's current Return-on-Tangible-Equity is -14.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamps Bio stock overvalued right now?
Hamps Bio (BOM:544312) has a current Return-on-Tangible-Equity of -14.04%. The current Return-on-Tangible-Equity is -14.04%. Hamps Bio's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Hamps Bio (BOM:544312), the current Return-on-Tangible-Equity is -14.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hamps Bio Ltd is engaged in the ethical marketing and distribution of pharmaceutical formulation products. Its product include tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products such as fruits, vegetables, herbs and flowers. The company segment includes Manufacturing, trading and distribution of Pharmaceutical formulation products and Manufacturing of Freeze dried and frozen products like fruits, vegetables, herbs, flowers, etc. Key revenue is generated from Medicine Products.
12GF Score
Get the complete analysis for BOM:544312
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544312 has been successfully added to your 
